Locally Ablative Therapies in Oligometastatic Breast Cancer - PubMed
12 hours ago
- #Ablative Therapy
- #Oligometastatic
- #Breast Cancer
- The study evaluates the impact of locally ablative therapies (surgery or ablation) on overall survival (OS) in patients with single-site oligometastatic de novo metastatic breast cancer (dnMBC).
- Retrospective analysis of 22,433 patients from the National Cancer Database (2010-2020) showed bone-only metastases were most common (68.8%).
- Locally ablative therapies were uncommon: BR+MT (6.4%), MT (10.6%), BR (15.3%) vs. no locally ablative therapy (NLT, 67.7%).
- Older age (>70 years) and higher comorbidity scores were associated with receiving NLT.
- BR (HR, 0.62) and BR+MT (HR, 0.60) were associated with improved OS compared to NLT, while MT alone (HR, 1.22) was linked to worse OS.
- The study suggests that resection of the primary breast tumor (BR) may be beneficial for patients with single-site dnMBC.